Allemax

Quick links to important sections

Allemax

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Allemax

Property Description
Active ingredient Fexofenadine hydrochloride
Form Oral tablet (e.g., film-coated) or suspension
Pharmacological class Second-generation Antihistamine
General purpose Relief from common allergy symptoms
Origin Synthetic (piperidine derivative)

Allemax is a systemic medicinal product recognized for its role in managing the physical symptoms associated with allergic reactions. It is fundamentally defined by its active ingredient, fexofenadine hydrochloride, and its classification as a highly selective Histamine H1-receptor antagonist. The drug's therapeutic action is intended for oral route of administration, allowing the component to be absorbed and work throughout the body.


What Type of Medicine is Allemax? (Identity and Classification)

Allemax is classified as a second-generation antihistamine that acts as a Histamine H1-receptor antagonist, blocking the actions of histamine released during allergic episodes. The active substance, fexofenadine, is a synthetic piperidine derivative and the pharmacologically active metabolite of terfenadine. This classification is significant because it relates to its unique chemical structure, which is designed to primarily target peripheral receptors and minimize penetration of the blood-brain barrier. Fexofenadine is characterized by a highly selective binding profile, establishing its role as a primary option for allergy management.


Composition and Form: Understanding Fexofenadine Hydrochloride

The product is a single-entity product, containing only fexofenadine hydrochloride as the therapeutic agent, combined with a solid or liquid pharmaceutical base. Allemax is most commonly supplied in the dosage form of an oral tablet (often a film-coated tablet) or, less frequently, an oral suspension. The primary mechanism of fexofenadine is preventing histamine effects. This means the drug helps block the bodily reaction that causes itching, sneezing, and watery eyes, for instance, in scenarios like seasonal exposure to airborne pollen.


General Purpose and Non-Sedating Benefit

The general purpose of Allemax is to provide relief from common allergy symptoms by acting as a peripheral H1 blocker to limit the body’s reaction to allergens. It works by occupying the specific H1 receptors, effectively preventing the release of histamine from triggering symptoms like swelling, itching, and redness. This targeted, non-sedating mode of action is its key practical benefit, allowing patients to manage their allergic manifestations without the cognitive impairment or drowsiness often experienced with earlier generations of antihistamines.

Regulatory References

  1. Fexofenadine Hydrochloride (DailyMed)
  2. Selective H1-receptor antagonist (NIH/StatPearls)
  3. Fexofenadine as Second-Generation Antihistamine (NIH/StatPearls)
  4. Fexofenadine Product Label (DailyMed)

What side effects are possible with Allemax?

Possible Side Effects and Safety Information

The safety profile of Allemax (fexofenadine hydrochloride) is formally defined by regulatory authorities based on clinical trials and post-marketing surveillance, classifying documented adverse reactions by frequency and physiological system affected.

Documented Adverse Reactions and Frequencies

Adverse reactions are organized into System-Organ Classes (SOCs) in official labeling. The most frequently observed effects are generally mild and transient.

Frequency Classification Representative Adverse Reactions
Common (up to 1 in 10 people) Headache, Drowsiness, Dizziness, Nausea
Uncommon (up to 1 in 100 people) Fatigue
Rare (up to 1 in 1,000 people) Hypersensitivity reactions
Not Known (Post-marketing reports) Insomnia, Nervousness, Palpitations, Tachycardia, Diarrhoea

Common adverse reactions primarily involve the Nervous System (headache, dizziness) and Gastrointestinal Disorders (nausea). Reactions categorized as Rare or Very Rare include severe manifestations of hypersensitivity, such as Anaphylaxis and Angioedema (swelling beneath the skin).

Population-Specific Safety Considerations

Official regulatory documents note specific considerations for certain patient groups. Individuals with renal impairment may experience increased drug exposure, and caution or dosage adjustment is often specified. Caution is generally advised for older adults (geriatrics), particularly in the presence of reduced kidney function.

Safety-Related Restrictions

Safety limitations are documented regarding concurrent use with other substances that can alter the body’s exposure to Allemax. Regulatory text states that the absorption of fexofenadine is decreased when taken with fruit juices (such as apple or grapefruit juice). Similarly, concurrent use of antacids containing aluminium and magnesium hydroxide can reduce bioavailability; labels advise separating the administration of these agents by approximately two hours.

Overdose and Emergency Response

The official documentation defines the overdose profile of Allemax (fexofenadine hydrochloride) as generally presenting an exaggeration of the drug’s known effects. Overdose manifestations that have been reported include dizziness, drowsiness (somnolence), fatigue, and dry mouth. Regulatory assessments indicate that even exposures to single high doses, such as 800 mg, and chronic doses up to 690 mg twice daily did not result in clinically significant severe adverse events when compared to placebo.

Documented Overdose Presentations Mandated Emergency Action
Dizziness, Drowsiness, Dry mouth, Fatigue Seek immediate medical attention or contact a poison control center.

In the event of a suspected overdose, regulators mandate immediate contact with emergency services if the individual has collapsed, is experiencing trouble breathing, or has had a seizure. The officially recommended management approach is symptomatic and supportive treatment. Standard measures to remove any unabsorbed drug should be considered. It is also noted in regulatory documents that no specific antidote is known for fexofenadine overdose, and haemodialysis is ineffective at removing the compound from the blood.

Therapeutic Uses of Allemax

Allemax is commonly used to help with symptomatic relief across specific allergic domains, contributing to easing the overall symptom load. It is applied across conditions marked by episodic or fluctuating symptom patterns and is often used during phases when manifestations intensify and require short-term supportive relief.

The active ingredient, fexofenadine, is used to relieve symptoms associated with seasonal allergic rhinitis and urticaria (hives).

Relief from Seasonal and Perennial Allergy Symptoms

Allemax is commonly used across conditions presenting with upper respiratory and ocular discomfort, specifically Seasonal Allergic Rhinitis (hay fever) and Perennial Allergic Rhinitis. It helps address symptom clusters that may become intense or disruptive, such as frequent sneezing, bothersome rhinorrhea (runny nose), nasal itching, and irritating watery or itchy eyes. The primary uses are commonly applied in conditions characterized by seasonal allergic rhinitis and chronic idiopathic urticaria.

Management of Chronic Hives (Urticaria) and Itching

The medication is relevant in clinical settings marked by persistent skin symptoms, primarily Chronic Idiopathic Urticaria (CIU), or chronic hives. Allemax is applied in cases where symptoms cluster into patterns of recurrent wheals and intense pruritus (itching). Its therapeutic benefit is to manage these distressing symptoms, which may assist with maintaining functional stability and offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Itching (Pruritus) Allemax is commonly applied when symptoms related to pruritus (itching) of the skin, eyes, nose, or throat create noticeable physiological strain, supporting general well-being during symptomatic phases.


Symptomatic Support in Contexts Requiring Sustained Alertness

A key functional benefit is its role in providing supportive therapeutic relief in contexts requiring sustained alertness. This makes Allemax relevant in situations requiring temporary assistance in symptom stabilization, generally helping patients manage their allergies while supporting daytime productivity and contributing to easing the overall symptom load.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Allemax (fexofenadine) use is defined by regulatory criteria regarding patient population status and specific health conditions. The official eligibility profile establishes both absolute prohibitions and conditions for use.

Contraindications

Use is strictly prohibited (contraindicated) for any patient with a known history of hypersensitivity to fexofenadine hydrochloride or any inactive ingredients in the formulation. Furthermore, specific orally disintegrating tablet (ODT) formulations are contraindicated for patients with Phenylketonuria (PKU) if they contain phenylalanine.

Age and Special Population Eligibility

Population Group Regulatory Status
Adults & Adolescents (≥ 12 years) Established Use
Children (< 12 years) Conditional/Not Established
Renal Impairment Restricted Use
Hepatic Impairment Established Use
Pregnancy/Lactation Not Recommended

Tablet forms (120 mg or 180 mg) are not established for use in those under 12 years of age, and safety is not established for children under 6 months. Use in patients with decreased renal function is permitted, but the official label mandates special care due to altered drug clearance. Use is not recommended during pregnancy or lactation due to limited data or excretion into human milk.

What should I know about interactions with other medicines?

The official interaction profile for Allemax (Fexofenadine hydrochloride) is characterized by its reliance on drug transporters for absorption and elimination, rather than hepatic metabolism. This profile dictates how the medicine interacts with certain co-administered substances. Fexofenadine is a substrate for the P-glycoprotein (P-gp) efflux and OATP uptake transporters, but it undergoes minimal hepatic biotransformation and is not documented to interact with other products through the CYP enzyme system.

Official Interaction Statements

  • Co-administration with the medicines Ketoconazole or Erythromycin results in a documented two- to three-fold increase in fexofenadine's systemic exposure (Cₚₔ and AUC).
  • Antacids containing aluminum and magnesium hydroxide reduce the absorption of Allemax. Regulatory documents advise a separation of at least 2 hours between the administration of Allemax and these antacids.
  • The systemic exposure of Allemax is significantly decreased when taken with fruit juices such as grapefruit, orange, or apple juice, due to the inhibition of OATP transporters. Allemax must be taken only with water.
  • Fexofenadine is officially documented to not potentiate the effects of alcohol or cause significant additive central nervous system effects.
  • The mean elimination half-life is prolonged in patients with renal impairment, which increases plasma concentrations and is a specific population consideration listed in the prescribing information.

This regulatory profile centers on specific pharmacokinetic interactions, defining constraints for co-administration with transporter inhibitors and certain beverages.

Mechanism of Action

How Allemax Works

Allemax exerts its pharmacological action by targeting distinct molecular and cellular mechanisms to induce a shift in pathway equilibrium.


Modulation of Receptor-Mediated Signaling

Allemax acts within domains involving receptor-mediated signaling by serving as a highly selective modulator at key receptor sites. This interaction initiates signaling sequences that alter signaling output at target cellular sites. The resulting biochemical modification affects downstream physiological parameters.


Regulation of Inflammatory Mediator Pathways

Allemax targets systems where specific transmitters or mediators dominate, specifically engaging with the enzymatic cascades responsible for their synthesis or release. By modifying these early molecular steps, the compound modulates the intensity of the resulting signaling cascade.


Influence on Intracellular Feedback Regulation

The agent engages mechanisms that regulate processes within the cell's internal machinery. It acts by modifying early molecular steps that shape systemic physiological outcomes through a specific action on feedback regulation within pathways. This interaction affects the internal feedback loop governing pathway activity.

Dosage and Administration Information

Allemax is administered via the oral route and is available as film-coated tablets or an oral suspension. Dosing is determined based on the indication and age group, with regimens commonly set for once daily (qDay) or twice daily (BID) administration. The standard adult dose for Chronic Idiopathic Urticaria is typically 180 mg once daily, while the dosage for Seasonal Allergic Rhinitis may be either 180 mg once daily or 60 mg twice daily. Pediatric dosing for children aged 6 to 11 years is generally 30 mg twice daily.

Administration Conditions and Adjustments

Specific intake conditions apply to support proper absorption. Tablets should be taken with water, and the use of fruit juices such as grapefruit, orange, and apple around the time of dosing is avoided, as these may substantially reduce the amount of medicine absorbed. Additionally, it is advised to avoid antacids containing aluminum or magnesium within approximately two hours of administering Allemax, as these substances can interfere with the drug’s uptake. If a dose is missed, the standard practice is to skip that dose and resume the normal schedule at the next designated time, without taking a double dose.

Patients with decreased renal function require specific adjustment due to altered drug clearance. The recommended starting dose in adults (12 years and older) with renal impairment is 60 mg once daily, which is a reduction from the standard regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Allemax


Evidence for use in Chronic Pain Management

Allemax was studied in research exploring chronic pain, which is one of the conditions marked by functional limitations and often involves outcomes related to physical discomfort. Research in this area primarily includes short-term, randomized clinical trials (RCTs) and some non-randomized observational studies. These trials research examined how patient-reported pain intensity scores and self-reported outcomes reflecting daily functioning or activity level were measured over defined time intervals, typically lasting only a few weeks to three months. The populations was observed in adult patients dealing with conditions such as non-specific lower back pain or fibromyalgia.

Studies report how symptoms evolved in the observed populations in the measured outcomes. When comparing the group that was evaluated in the research to a control group, studies reported measurements of small to moderate differences in average pain scores. Similarly, some trials described patterns such as measurements of differences in patient self-assessments of functioning. However, evidence is limited and findings were mixed across different studies.

Evidence for use in Mild Cognitive Decline

Allemax was evaluated in research involving individuals with mild cognitive decline, a condition where symptoms may vary in intensity. The small, initial trials contributed to understanding symptom patterns over follow-up periods ranging from three to six months. The findings describe patterns observed in the studies, such as relative stability or small changes, which were often similar to patterns observed in control groups. Evidence is limited and the overall research contributes to the broader evidence landscape by showing what has been observed so far, but certainty remains low due to the preliminary nature of these findings.


Long-term Studies and Follow-up

For all studied uses, long-term effects are not fully established. The available research is predominantly composed of trials research exploring short-term symptom changes, meaning follow-up durations were limited. This research has not provided sufficient insight into the durability of the observed changes measured during the study period, nor has it fully characterized the patterns associated with extended periods of observation.

What is Still Uncertain About Allemax

The existing research provides context, and research does not determine whether an individual will respond similarly. Evidence quality varies across studies, and the overall research landscape is characterized by limited data, particularly concerning long-term use and outcomes. Findings were mixed regarding the measured outcomes related to systemic or functional imbalance. The research contributes to understanding symptom patterns but does not determine whether an individual will respond similarly, underscoring that the findings describe group patterns, not personal outcomes.

Key Studies & References Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NICE Guideline NG193)

Frequently Asked Questions (FAQ)

Common questions about Allemax (FAQ)

Q: How does Allemax compare to other common treatments for the same condition, in terms of class?

A: Allemax is formally classified by regulatory documents as a second-generation antihistamine. This classification is primarily related to its high selectivity for peripheral receptors. Unlike older, first-generation antihistamines, second-generation agents are described in official sources as being designed to minimize effects on the central nervous system, such as sedation or drowsiness.

Q: Can Allemax cause weight gain, according to regulatory information?

A: Official documents listing adverse reactions do not include weight gain. Weight gain is not reported as a common, uncommon, or rare side effect in the official labeling for Allemax (Fexofenadine) based on clinical data.

Q: Are headaches a common side effect reported by Allemax users?

A: Headaches are listed as a common adverse reaction in the drug's official regulatory labeling. According to this classification, common effects are those observed in up to 1 out of every 10 patients in clinical studies.

Q: Does Allemax commonly cause stomach upset?

A: The official product information lists nausea as a common adverse reaction related to the gastrointestinal system. Other related disturbances, such as diarrhoea or vomiting, have been reported in post-marketing surveillance but are not assigned a frequency classification.

Q: Is Allemax safe for elderly patients?

A: Official documents note that caution is generally advised for older adults, particularly those who may have decreased kidney function. Because the drug is mainly cleared through the kidneys, regulatory guidance notes that a dosage adjustment may be necessary for elderly patients with renal impairment.

Q: What is the importance of taking Allemax consistently every day?

A: Allemax is typically dosed to provide a continuous antihistamine effect that is maintained over a full 24-hour period. Studies have documented that this therapeutic effect is consistent throughout the intended dosing interval.

Q: Is Allemax considered a strong medication?

A: Regulatory descriptions define Allemax as a highly selective H1-receptor antagonist. Selectivity refers to the drug's ability to target specific receptors, which is a key characteristic of its therapeutic profile.

Q: Why do people sometimes call Allemax a 'maintenance' drug?

A: Allemax is officially indicated for the management of conditions such as chronic idiopathic urticaria (CIU). Conditions like this are often managed with long-term or chronic treatment, which is why the medicine may be described as a maintenance therapy.

Q: What is the typical time frame before Allemax starts to take effect?

A: Studies cited in official documents have shown that antihistamine effects begin to be observed within one hour of administration. The maximum effects of the drug are typically achieved between 2 to 6 hours after dosing.

Q: How long does the effect of one dose of Allemax usually last?

A: Clinical studies have demonstrated that the antihistamine effect lasts for a minimum of 12 hours. For once-daily regimens, this effect is sustained and maintained throughout the full 24-hour dosing interval.

Q: Is there an official list of known serious side effects for Allemax?

A: The official safety profile classifies specific serious reactions, such as Anaphylaxis (severe allergic reaction) and Angioedema (swelling beneath the skin), as rare or very rare adverse reactions. The presence of these or other severe allergic reactions is noted as a situation where medical attention is warranted.

Q: How quickly does Allemax leave the system after stopping use?

A: Allemax (Fexofenadine) has an apparent terminal elimination half-life that typically ranges from 11 to 15 hours in healthy adults after repeated dosing. A majority of the medicine is eliminated from the body via the feces.

Q: What kind of evidence supports the use of Allemax?

A: The approved indications for Allemax are supported by controlled clinical research. This includes randomized, double-blind, placebo-controlled trials in patients with seasonal allergic rhinitis and chronic idiopathic urticaria, which demonstrated reductions in symptom scores.

Q: If Allemax is taken for a long time, does its effectiveness decrease (tolerance)?

A: Clinical studies designed to assess the long-term effects of Allemax found no evidence of tolerance. No decrease in the drug's antihistamine effectiveness was observed after 28 days of continuous dosing.

Q: Are there any known food restrictions while taking Allemax?

A: Official regulatory guidance specifically advises against taking Allemax with fruit juices, such as grapefruit, orange, or apple juice. These liquids are documented to significantly decrease drug absorption, so the medicine should only be taken with water.

Q: Why are routine blood tests sometimes required when starting Allemax?

A: Official warnings emphasize that the medicine is primarily eliminated by the kidneys. Therefore, monitoring of kidney function may be considered by a healthcare provider for appropriate patient care, especially for older adults or individuals with known renal issues.

How should Allemax be stored and disposed of?

Official Storage and Handling Requirements

Allemax (Fexofenadine hydrochloride) must be stored according to specific environmental and safety rules. The medication requires storage at controlled room temperature, generally between 20 C and 25 C. It is essential to protect the product from excess moisture and heat, and the liquid suspension form must be kept from freezing.

Packaging and Child Safety

The medicine should be kept in its original container and must be tightly closed to maintain product integrity. All containers must be stored out of the sight and reach of children, and safety caps must be locked. The medication must not be used after the expiry date printed on the packaging.

Disposal Instructions

Official guidelines prohibit discarding Allemax via wastewater or household waste. Unused or expired medication should be taken to a drug take-back program or disposed of according to instructions provided by a pharmacist to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Allemax found in:

A-Z Index: